Daniel Sumarriva/LinkedIn
Jun 3, 2025, 14:09
Daniel Sumarriva Presented Poster on Tumor-Informed ctDNA Predicting Recurrence in Advanced Ovarian Cancer at ASCO 2025
Daniel Sumarriva, Executive Medical Director at SAGA Diagnostics, posted on LinkedIn:
“Proud moment at ASCO25!
Our SAGA Diagnostics poster on tumor-informed ctDNA as a predictive marker for relapse in advanced ovarian cancer drew much interest and discussion.
Findings show that ctDNA clearance at end of chemo (C6) predicts recurrence risk better than CA-125 especially in patients with complete cytoreduction.
Amazing to connect with so many colleagues and showcase the power of Pathlight MRD technology by Team SAGA.
Thank you for the support and enthusiasm!”
More posts featuring Daniel Sumarriva on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 2, 2025, 20:46
Jul 2, 2025, 20:25
Jul 2, 2025, 20:16
Jul 2, 2025, 16:01